✦ LIBER ✦

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

✍ Scribed by Alastair M. Thompson; Andrea Johnson; Philip Quinlan; Grantland Hillman; Marcel Fontecha; Susan E. Bray; Colin A. Purdie; Lee B. Jordan; Roberta Ferraldeschi; Ayshe Latif; Kirsten D. Hadfield; Robert B. Clarke; Linda Ashcroft; D. Gareth Evans; Anthony Howell; Michele Nikoloff; Jeffrey Lawrence; William G. Newman

Publisher: Springer US
Year: 2010
Tongue: English
Weight: 321 KB
Volume: 125
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-010-1139-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Potent CYP2D6 Inhibiting drugs do not in

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

✍ Nava Siegelmann-Danieli; Daniel Kurnik; Yossi Lomnicky; Janet Vesterman-Landes; 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 170 KB

Prevalent breast cancer patients with a

Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

✍ A. S. Dieudonné; D. Lambrechts; B. Claes; T. Vandorpe; H. Wildiers; D. Timmerman 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 224 KB

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Masatsugu Okishiro; Tetsuya Taguchi; Seung Jin Kim; Kenzo Shimazu; Yasuhiro Tama 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 469 KB 👁 1 views

Reply to Genetic polymorphisms of CYP2D6

Reply to Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Shinzaburo Noguchi; Masatsugu Okishiro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 1 views

Lack of any association between function

Lack of any association between functionally significantCYP2D6polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment

✍ In Hae Park; Jungsil Ro; Sohee Park; Hyeong-Seok Lim; Keun Seok Lee; Han Sung Ka 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 333 KB